Clinical trials: Dry Eye Disease
Dry Eye Disease
Study Evaluating the Safety and Efficacy of AR-15512
This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED).
- Trial name
- COMET-2 (NCT05285644)
- Testing
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Where
- 23 sites in United States
- Volunteers
- 465 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye
Kynex Versus Refresh Plus Study in Subject With Dry Eye
The effect of Kynex versus Refresh Plus in subjects with mild to moderate dry eye.
- Trial name
- NCT00809198
- Testing
- Sodium Hyaluronate, Carboxymethylcellulose sodium
- Volunteers
- 67 people
- Sponsor
- Alcon Research
Dry Eye
The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study
In patients with dry eye, defined as corneal staining and a reduced tear breakup time, lifitegrast will improve higher order aberrations, ocular scatter index, corneal staining, and TBUT as soon as 1 week after initiating…
- Trial name
- CLEAR (NCT04669561)
- Testing
- Lifitegrast 5% Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Eyes Dry Chronic
ESBA105 in Patients With Severe Dry Eye
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01338610
- Testing
- ESBA105 ophthalmic solution, ESBA105 vehicle
- Where
- United States
- Volunteers
- 334 people
- Sponsor
- Alcon Research
Sjögren's Syndrome
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren's related Dry Eye Disease.
- Trial name
- NCT07118241
- Testing
- Recombinant Human Proteoglycan 4, Vehicle Control
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Lubris Bio Pty Ltd
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Dry Eye Disease
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease.
- Trial name
- BUSTON-01 (NCT05865379)
- Testing
- BUFY01 eye drops in single-dose containers, SVS20 eye drops in single-dose containers
- Where
- 3 sites in Belgium, France
- Volunteers
- 80 people
- Sponsor
- TRB Chemedica International SA
Dry Eye
A Natural History Study of Patients With Dry Eye
This is a multi-center, prospective, controlled, observational study of the natural history of patients with dry eye disease.
- Trial name
- NCT00833235
- Testing
- Artificial Tears
- Where
- 17 sites in United States
- Volunteers
- 284 people, healthy volunteers welcome
- Sponsor
- Allergan
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Sjogren's Syndrome
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
- Trial name
- NCT03100942
- Testing
- Lanraplenib, Filgotinib, Tirabrutinib
- Where
- 53 sites in United States, Poland and 2 more
- Volunteers
- 152 people
- Sponsor
- Gilead Sciences
Dry Eye Syndromes, Dry Eye
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- ARISE-3 (NCT03937882)
- Testing
- RGN-259
- Where
- 20 sites in United States
- Volunteers
- 700 people
- Sponsor
- ReGenTree, LLC
Dry Eye
Phase 1 Study for Safety and Tolerability of HL036
To evaluate the safety, local tolerability and pharmacokinetic characteristics after administration of eye-drop HL036 in healthy Korean male volunteers
- Trial name
- NCT02717208
- Testing
- HL036, Vehicle
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Dry Eye
Comparison of Frequency of Use of Optive and Systane
The purpose of this study is subjectively compare duration of action between Optive and Systane.
- Trial name
- NCT00406510
- Testing
- Optive, Systane
- Where
- United States
- Sponsor
- Innovative Medical
Dry Eye
Evaluation of Dry Eye by Tear Film Imager in a Low Humidity Environmental Exposure Chamber (TFI-LH16)
The study consists of 3 study visits to the clinic over at least 9 days. Visit 1 - the medical screening visit: subjects will undergo informed consent and will be tested for signs and symptoms of Dry Eye Syndrome (DES) including…
- Trial name
- TFI-LH16 (NCT03061578)
- Testing
- Tear Film Imager, Low Humidity Environmental Exposure Chamber (LH-EEC)
- Where
- Canada
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Adom Advanced Optical Technologies Ltd.
Dry Eye
Systane® Hydration PF and Systane® Hydration Preserved
The purpose of this post-market clinical follow-up (PMCF) study is to assess the performance and safety of Systane Hydration Preservative Free (PF) in subjects experiencing dry eye symptoms (Group 1) and in contact lens (CL)…
- Trial name
- NCT05932238
- Testing
- Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF), Polyethylene glycol 400 and propylene glycol solution/drops - Preserved
- Where
- 3 sites in Canada
- Volunteers
- 137 people
- Sponsor
- Alcon Research
Dry Eye
The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye.
- Trial name
- NCT01250171
- Testing
- Secukinumab 10 mg/kg, Canakinumab 10 mg/kg
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjögren Syndrome, Dry Eye
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated…
- Trial name
- NCT03226444
- Testing
- 0.005% Lacripep, 0.01% Lacripep
- Where
- 35 sites in United States
- Volunteers
- 204 people
- Sponsor
- TearSolutions, Inc.
Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
This is a phase I, open-label study of ATG-201 in participants with autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
- Trial name
- ATTRACT (NCT07732309)
- Testing
- ATG-201
- Where
- 22 sites in China
- Volunteers
- 149 people
- Sponsor
- Antengene Biologics Limited
Dry Eye
The COAT Trial: Cequa's Onset of Action Trial
Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients
- Trial name
- COAT (NCT06482177)
- Testing
- Cyclosporine ophthalmic solution
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Dry Eye
Acute Comfort and Blur of Systane Ultra and Systane
To evaluate drop comfort, acceptability, preference and blue profile between two marketed artificial tears in both dry eyes and non-dry eye patient population.
- Trial name
- NCT00748865
- Testing
- Systane Ultra Lubricant Eye Drops, Systane Lubricant Eye Drops
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Alcon Research